EDF Annual Meeting 2022 will be conducted VIRTUALLY – Face-to-face meeting in Montreux cancelled
Dear EDF Members/Guests/Corporate Partners,
After careful consideration of the current Corona developments in Switzerland and taking into account the significantly increasing numbers of infections each day, I very much regret to inform you that the EDF Board has decided to cancel the face-to-face meeting in Montreux this year. Over the last weeks, the highly infectious nature of the Omicron variant has become clear and we strongly feel that the risk to your personal safety through a face-to-face meeting would be too high even with strict safety protocols in place.
Although we are aware of the fact that a virtual alternative will not be able to replace the spirit of a live meeting, we will proceed with a slimmer online version of the program. A detailed schedule including login details to access the meeting will be provided next week.
Obviously, we will also refund the dinner fee for the Casino evening. We kindly ask you for your understanding that this will take a couple of days.
Hotel cancellation policy:
All hotel reservations, which have been made through our EDF website hotel platform, will be cancelled by the EDF Convention Team.
All other bookings made via other booking platforms or directly with the hotel should be cancelled by the attendees themselves free of charge at least 7 days prior to their planned arrival. We therefore kindly ask you to cancel your booking in due time.
Contact details hotel:
Yana Maillard | Sales Manager | yana.maillard@brhhh.com
Grand Hôtel Suisse Majestic | Avenue des Alpes 45, 1820 Montreux | Tél. +41 21 966 33 07 | Fax +41 21 966 33 01|
I thank you very much for your understanding and I’m looking forward to seeing you all (at least virtually) soon.
Stay safe and all the best wishes,
Alexander Enk
EDF President
Statement on the Coronavirus (COVID-19) Outbreak
Dear EDF members,
The coronavirus (COVID-19) infection is rapidly spreading all over the world and is a big concern for the public health. While ad hoc guidelines are not available yet, dermatologists are facing the dilemma of how to approach patients under treatment with biologics and/or immunosuppressants, or in need for these therapies. Although clinicians can still make individually based decisions, or be guided by their own health service, the EDF invites you to consider the statements released by the International Psoriasis Council (IPC) and the British Association of Dermatologists (BAD).
www.psoriasiscouncil.org
www.skinhealthinfo.org.uk
